Alterity Therapeutics (PRNAD) EBITDA (2009 - 2024)

Alterity Therapeutics (PRNAD) has reported EBITDA for 8 consecutive years, with -$12.8 million the latest figure, recorded in Q2 2024.

• In Q2 2024, EBITDA fell 36.64% year-over-year to -$12.8 million; the TTM figure through Jun 2024 stood at -$12.8 million (down 36.64% YoY), while the FY2025 annual figure was -$7.7 million, up 39.35% from the prior year.
• EBITDA came in at -$12.8 million for Q2 2024 at Alterity Therapeutics, down from -$9.3 million in the prior quarter.
• The five-year high for EBITDA was -$9.3 million in Q2 2022, with the low at -$12.8 million in Q2 2024.
• Average EBITDA over 3 years is -$10.5 million, with a median of -$9.3 million recorded in 2023.
• Across the five-year window, EBITDA retreated 0.1% in 2023 and plunged 36.64% in 2024, its largest moves.
• Year by year, EBITDA stood at -$9.3 million in 2022, then fell by 0.1% to -$9.3 million in 2023, then slumped by 36.64% to -$12.8 million in 2024.
• According to Business Quant data, EBITDA over the past three periods registered -$12.8 million, -$9.3 million, and -$9.3 million for Q2 2024, Q2 2023, and Q2 2022 respectively.